Breaking News Instant updates and real-time market news.

WMT

Walmart

$86.07

1.56 (1.85%)

, CSCO

Cisco

$45.16

-0.32 (-0.70%)

08:52
05/17/18
05/17
08:52
05/17/18
08:52

On The Fly: Pre-market Movers

UP AFTER EARNINGS: Walmart (WMT), up 1.7%. ALSO HIGHER: Loxo Oncology (LOXO), up 13% after announcing data on LOXO-292 ahead of a planned presentation at the upcoming ASCO meeting of cancer researchers... NXP Semiconductors (NXPI), up 1% amid optimism about its deal with Qualcomm (QCOMM) on the heels of the report that China will allow the proposed $18B sale of Toshiba's (TOSBF) chip unit to a Bain Capital-led consortium... WWE (WWE), up 10% after Guggenheim analyst Curry Baker presented a "bullish" view on the company's TV renewal prospects in a note to investors. DOWN AFTER EARNINGS: J.C. Penney (JCP), down 10%... Cisco (CSCO), down 4%... NetEase (NTES), down 9%... Children's Place (PLCE), down 3%. ALSO LOWER: Jounce Therapeutics (JNCE), down 33% after the company's report of 'underwhelming' JTX2011 data ahead of the ASCO meeting led to a downgrade of the stock at Wells Fargo... Blueprint Medicines (BPMC), down 7% after last night's release of abstracts ahead of the upcoming ASCO meeting.

WMT

Walmart

$86.07

1.56 (1.85%)

CSCO

Cisco

$45.16

-0.32 (-0.70%)

NTES

NetEase

$266.00

-0.26 (-0.10%)

JNCE

Jounce Therapeutics

$17.66

1.055 (6.35%)

LOXO

Loxo Oncology

$138.95

-1.48 (-1.05%)

NXPI

NXP Semiconductors

$108.87

-1.23 (-1.12%)

QCOM

Qualcomm

$56.72

1.1 (1.98%)

WWE

WWE

$43.58

-0.07 (-0.16%)

BPMC

Blueprint Medicines

$86.12

5.22 (6.45%)

PLCE

Children's Place

$137.85

2.55 (1.88%)

  • 17

    May

  • 17

    May

  • 23

    May

  • 30

    May

  • 30

    May

  • 01

    Jun

  • 01

    Jun

  • 07

    Jun

  • 10

    Jul

WMT Walmart
$86.07

1.56 (1.85%)

05/15/18
SPHN
05/15/18
NO CHANGE
Target $108
SPHN
Overweight
Walmart Q1 expectations achievable, says Stephens
Stephens analyst Ben Bienvenu said he believes that consensus expectations regarding Walmart's Q1 results are achievable, though he noted that e-commerce growth in the quarter may come in below the company's annual guidance for about 40% growth. Still, easier e-commerce comparisons as the year progresses make its annual goals doable and Bienvenu remains confident that Walmart is one of the best positioned retailers he covers, he tells investors. He maintains an Overweight rating and $108 price target on Walmart ahead of the company's earnings report due on Thursday.
05/10/18
LOOP
05/10/18
NO CHANGE
Target $87
LOOP
Hold
Walmart price target lowered to $87 from $92 at Loop Capital
Loop Capital analyst Andrew Wolf lowered his price target on Walmart to $87 and kept his Hold rating after the company's $16B investment in Flipkart. The analyst is positive on the deal longer term, given that India's retail market is expected to grow at 9% per year over the next 5 years and in light of the company's minimal store presence in India. In the medium term however, Wolf says the investment will be "meaningfully dilutive" to earnings, weighing on the stock.
05/10/18
MSCO
05/10/18
NO CHANGE
Target $93
MSCO
Equal Weight
Walmart deal for Flipkart more dilutive than anticipated, says Morgan Stanley
Morgan Stanley analyst Simeon Gutman noted that news reports heading up to Walmart's (WMT) deal for a majority stake in Flipkart had predicted a $12B transaction for about 60% of a business generating operating losses in the $1B range. However, the higher than expected magnitude of losses Walmart would absorb in India significantly raises the stakes on the trajectory of its U.S. business and clouds the near-term path, he said. He also questions why the company is investing outside the U.S. market, stating that it could have instead accelerated its third-party marketplace infrastructure, stepped up its partnership with Google Home (GOOG) to better compete with Amazon's (AMZN) Alexa, or intensified domestic investments in price and fulfillment. However, he does add that the deal prevents Amazon, for now, from building an "insurmountable" advantage in the important Indian market. Gutman lowered his price target on Walmart to $93 from $99 after the deal was more dilutive than anticipated and keeps an Equal Weight rating on the shares.
05/16/18
MKMP
05/16/18
NO CHANGE
Target $93
MKMP
Buy
Target to benefit from strong digital sales, says MKM Partners
MKM Partners analyst Patrick McKeever kept his Buy rating and $93 price target on Target Corp (TGT) ahead of its Q1 earnings next week. The analyst says the aggressive Street consensus for earnings is "doable" in spite of the negative impact from cold weather in the East, noting that the quarter will likely see more strong growth in digital sales driven by more "expedient" fulfillment and new orders. McKeever adds that despite the 12% run in the stock price year-to-date, its valuation is still 3.4 points below that of Walmart (WMT) on "overly pessimistic" investor sentiment. The analyst says Target remains his "Top Pick" in the space in 2018.
CSCO Cisco
$45.16

-0.32 (-0.70%)

05/17/18
JMPS
05/17/18
NO CHANGE
JMPS
Market Perform
Cisco results bode well for Arista, Nutanix and Palo Alto, says JMP Securities
JMP Securities analyst Erik Suppiger said Cisco (CSCO) noted strength in data center and campus switching in its Q3 earnings report, which suggests to him that demand trends are favorable for Arista Networks (ANET). In the DC business, Cisco noted it grew double digits year-over-year driven by its hyperconverged infrastructure product, which Suppiger sees pointing to favorable demand for Nutanix (NTNX). Additionally, security sales re-accelerated in the quarter to double-digit growth for the first time in over a year, which the analyst reads as a favorable trend for Palo Alto Networks (PANW). On Cisco itself, Suppiger said he sees the stock as fairly valued and he maintains a Market Perform rating on the shares.
05/17/18
BARD
05/17/18
NO CHANGE
Target $51
BARD
Outperform
Cisco weakness a buying opportunity, says Baird
Baird analyst Jayson Noland said Cisco posted a solid quarter on nearly all metrics and recommended buying the dip in the shares. The analyst said the selloff was due in part to high expectations against its in-line Q4 guidance. Noland reiterated his Outperform rating and $51 price target on Cisco shares.
05/17/18
UBSW
05/17/18
NO CHANGE
Target $51
UBSW
Buy
Cisco business model progress encouraging, says UBS
UBS analyst Steven Milunovich noted Cisco's results were in-line, with revenue growth and EPS slightly ahead of consensus. He views public cloud and competition as headwinds, but finds the business model and culture changes as encouraging. Milunovich reiterated his Buy rating and $51 price target on Cisco shares.
05/17/18
FBCO
05/17/18
NO CHANGE
Target $41
FBCO
Neutral
Cisco in transition in shift towards recurring revenue model, says Credit Suisse
Credit Suisse analyst Sami Badri maintained a Neutral rating and $41 price target on Cisco Systems following the company's in-line Q3 results, which were driven by product revenue, which increased 4.7% year-over-year, outpacing services revenue growth of 3.4% y/y. In a research note to investors, Badri called out Cisco as "the leading and most dominant player" across several communications and networking markets, but stressed that the company remains in transition as its business is shifted towards a more software/recurring revenue model.
NTES NetEase
$266.00

-0.26 (-0.10%)

04/10/18
JEFF
04/10/18
NO CHANGE
Target $310
JEFF
Hold
NetEase price target lowered to $310 from $335 at Jefferies
Jefferies analyst Karen Chan lowered her price target for NetEase to $310 from $335, while reiterating a Hold rating on the shares. The analyst remains long-term positive on its gaming franchise and expects mobile games to resume quarter over quarter growth in Q1, but notes she will need further evidence of either more new hits or newly-launched titles performing better in order to justify upside to her 20% FY18 mobile game growth forecast. Rising competition for gamer time spent, increased promotional effort and revenue mix change poses downside risk to FY18/19 consensus earnings, Chan contends.
04/12/18
JPMS
04/12/18
INITIATION
Target $240
JPMS
Underweight
NetEase resumed with an Underweight at JPMorgan
JPMorgan analyst Alex Yao resumed coverage of NetEase with an Underweight rating and $240 price target. Prior to restricting the stock in 2016, the firm had an Overweight rating on the shares. The analyst views 2018 as a transition year for NetEase in terms of game genre and geographic market. The biggest revenue driver of NetEase in the past few years, PC IP migration to mobile, "has already been exhausted," Yao tells investors in a research note. He believes NetEase is entering a "structurally less profitable stage" due to lower per gamer monetization.
04/25/18
LYON
04/25/18
UPGRADE
LYON
Outperform
NetEase upgraded to Outperform from Underperform at CLSA
CLSA upgraded NetEase to Outperform from Underperform, mainly citing valuation, adding that the company could see a rebound in gaming revenues in Q1.
05/17/18
BNCH
05/17/18
NO CHANGE
Target $340
BNCH
Buy
NetEase price target lowered to $340 from $355 at Benchmark
Benchmark analyst Fawne Jiang lowered her price target on NetEase to $340 from $355, citing near-term margin pressure following the company's report of mixed Q1 results. While its revenue beat was mainly driven by the resumption of mobile gaming growth and continued momentum of the ecommerce businesses, NetEase's earnings underperformance was mainly due to higher operating expenses and higher copyrights related costs, said Jiang, who keeps a Buy rating on the stock.
JNCE Jounce Therapeutics
$17.66

1.055 (6.35%)

05/17/18
HCWC
05/17/18
NO CHANGE
Target $19
HCWC
Buy
Jounce Therapeutics price target lowered to $19 from $33 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Jounce Therapeutics to $19 citing the "limited activity on show" for JTX-2011, either as a monotherapy or when used in combination with Opdivo. With the stock already down today, "a reactionary downgrade here would make little sense," Chattopadhyay tells investors in a research note. He keeps a Buy rating on the shares.
05/17/18
WELS
05/17/18
DOWNGRADE
WELS
Market Perform
Jounce Therapeutics downgraded to Market Perform from Outperform at Wells Fargo
04/27/18
04/27/18
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Jounce Therapeutics (JNCE) initiated with a Buy at H.C. Wainwright. 2. Gaia (GAIA) initiated with a Buy at Roth Capital. 3. Inter Pipeline (IPPLF) initiated with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/17/18
WELS
05/17/18
DOWNGRADE
Target $13
WELS
Market Perform
Wells Fargo downgrades Jounce on 'underwhelming' JTX2011 data
Wells Fargo analyst Jim Birchenough downgraded Jounce Therapeutics to Market Perform from Outperform and cut his price target for the shares to $13 from $37. The stock in premarket trading is down 31%, or $5.43, to $12.24. Overall response rates for JTX-2011 monotherapy in gastric cancer and in triple negative breast cancer, as well as for JTX-2011 plus Opdivo in gastric cancer and in triple negative breast cancer are "underwhelming" and "not competitive with other investigational drugs," Birchenough tells investors in a research note following review of the ASCO abstract. He advises taking a "wait and see approach to assess strength of aggregate data."
LOXO Loxo Oncology
$138.95

-1.48 (-1.05%)

04/16/18
04/16/18
UPGRADE
Target $170

Overweight
Loxo Oncology upgraded to Overweight after competitor data at Morgan Stanley
As previously reported, Morgan Stanley analyst Matthew Harrison upgraded Loxo Oncology (LOXO) to Overweight from Equal Weight after competitor Blueprint Medicines (BPMC) provided initial data at the AACR meeting on its RET inhibitor BLU-667 that he believes was at the lower-end of Loxo investors' expectations from a competition standpoint. He now believes Loxo has an opportunity to demonstrate differentiation on both efficacy and safety for LOXO-292 versus BLU-667 when updated data are presented at the ASCO meeting in June. Harrison, who sees the most opportunity for LOXO-292 being a better adverse effect profile, raised his price target on Loxo shares to $170 from $130.
05/09/18
JMPS
05/09/18
NO CHANGE
Target $152
JMPS
Outperform
Loxo Oncology price target increased to $152 from $95 at JMP Securities
JMP Securities analyst Konstantinos Aprilakis raised his price target on Loxo Oncology to $152 from $95 following an update to his financial model after the company's Q1 earnings report, which he said highlighted its pipeline progress. He maintains an Outperform rating on Loxo shares.
05/17/18
STFL
05/17/18
NO CHANGE
Target $190
STFL
Buy
Loxo Oncology price target raised to $190 after ASCO abstracts at Stifel
Stifel analyst Stephen Willey said he believes the preliminary efficacy data on Loxo Oncology's (LOXO) LOXO-292 that was reported in abstracts released last night in anticipation of the ASCO meeting should further distance the candidate from other competitive RET inhibitors. The overall response rate, or ORR, of 52% reported for the 46 evaluable patients harboring RET-altered tumors tops the 46% ORR previously-reported for competitor Blueprint Medicines' (BPMC) BLU-667 at AACR, noted Willey. The analyst, who also thinks the disclosure of this data increases visibility for potential strategic buyers who have historically shown a "willingness to pay top-dollar for long-duration targeted oncology agents," increased his price target on Loxo to $190 from $145 and keeps a Buy rating on the shares.
04/16/18
STFL
04/16/18
NO CHANGE
STFL
Buy
Blueprint data leaves 'door wide open' for Loxo's LOXO-292, says Stifel
Stifel analyst Stephen Willey noted that Blueprint Medicines (BPMC) reported data from the dose-escalation portion of its Phase 1 trial of BLU-667 at this weekend's AACR meeting. He believes BLU-667 looks like "a sufficiently viable asset for RET-altered tumors," but he also thinks the data has left the competitive window "wide-open" for Loxo Oncology (LOXO) ahead of preliminary LOXO-292 data expected at the ASCO meeting in June. Loxo's data now potentially could shift sentiment on what consensus has been presuming to be a $1B+ opportunity equally-shared between the two companies, Willey tells investors. He maintains a Buy rating on Loxo shares.
NXPI NXP Semiconductors
$108.87

-1.23 (-1.12%)

05/03/18
RHCO
05/03/18
NO CHANGE
Target $119
RHCO
Buy
NXP quarter does not confirm bear thesis, says SunTrust
SunTrust analyst William Stein says NXP Semiconductors' (NXPI) miss in Q1, while a bad print, does not confirm the bear thesis on the shares, which he believes centers around a "disengaged management team and a broken product portfolio." Despite the Q1 miss management remains engaged, and the product portfolio "remains robust," Stein tells investors in a post-earnings research note. He thinks management will only demonstrate engagement if the Qualcomm (QCOM) deal breaks. The analyst lowered his price target for NXP Semiconductors to $119 from $121 and keeps a Buy rating on the shares.
05/03/18
05/03/18
UPGRADE
Target $127.5

Buy
NXP Semiconductors upgraded to Buy on deal closure optimism at Drexel Hamilton
As previously reported, Drexel Hamilton analyst Cody Acree upgraded NXP Semiconductors (NXPI) to Buy from Hold, citing his optimism about the company closing its merger with Qualcomm (QCOM). While still working to satisfy MOFCOM regulatory approval, NXP reported results that were largely in-line with his seasonal expectations and consistent with the positive industry trends being seen from most of the analog group, Acree tells investors. He raised his price target on NXP shares to $127.50 from $110.
05/03/18
DRXL
05/03/18
UPGRADE
DRXL
Buy
NXP Semiconductors upgraded to Buy from Hold at Drexel Hamilton
05/03/18
BERN
05/03/18
NO CHANGE
Target $115
BERN
Market Perform
NXP Semiconductors price target lowered to $115 from $125 at Bernstein
Bernstein analyst Stacy Rasgon lowered her price target for NXP Semiconductors to $115 from $125 after its Q1 results missed. The analyst reiterates a Market Perform rating on the shares.
QCOM Qualcomm
$56.72

1.1 (1.98%)

04/27/18
RHCO
04/27/18
UPGRADE
Target $121
RHCO
Buy
NXP Semiconductors upgraded to Buy at SunTrust on attractive price entry
As reported earlier, SunTrust analyst William Stein upgraded NXP Semiconductors (NXPI) to Buy, saying that the selloff from the re-filing by Qualcomm (QCOM) for its acquisition with China's Commerce Ministry has taken the stock to "compelling" levels. The analyst contends that even if the deal does not close, the company's stand-alone value is modeled at $121, implying an 18% return from the current level. Stein lowers his price target to $121 from $127.50 as part of his upgrade but sees the "bull case" scenario leading to $135 stock price .
04/26/18
BMOC
04/26/18
NO CHANGE
Target $55
BMOC
Market Perform
Qualcomm price target lowered to $55 from $70 at BMO Capital
BMO Capital analyst Tim Long lowered his price target on Qualcomm (QCOM) to $55 and kept his Market Perform rating. Long says that despite the "favorable" Q2 results, the company announced "much weaker" guidance for the June quarter, noting that while the chip business continues to deliver, the "outlook for royalties is negative". Aside from the ongoing disputes with Apple (AAPL) and Huawei, the analyst points to reduced royalty rates from other licensees, including a lower effective rate from Samsung (SSNLF). Long prefers a neutral stance amid the "ongoing uncertainty around licensing, as well as multiple regulatory investigations".
WWE WWE
$43.58

-0.07 (-0.16%)

05/04/18
05/04/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Fluor (FLR) downgraded to Neutral from Outperform at Baird with analyst Andrew Wittmann saying his thesis was based on the early stage commodity cycle recovery and now he sees too few catalysts remaining in a difficult environment for industrials. 2. Diebold (DBD) downgraded to Neutral from Outperform at Credit Suisse with analyst Paul Condra saying he expects a longer turnaround to the story, and prefers a wait-and-see approach as the company's management team moves forward with another round of restructuring initiatives, the details of which have not yet been announced. 3. AMN Healthcare (AMN) downgraded to Neutral from Outperform at Baird with analyst Mark Marcon saying the boost from premium rate assignments appear to be slowing. 4. WWE (WWE) downgraded to Hold from Buy at Benchmark with analyst Mike Hickey citing valuation after the stock's 109% rise over the last year. 5. Colfax (CFX) downgraded to Sector Perform from Outperform at RBC Capital with analyst Seth Weber citing material inflation in the A&GH segment, pressuring continued expansion in margins and organic revenue growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/04/18
SBSH
05/04/18
NO CHANGE
Target $43
SBSH
Neutral
WWE price target raised to $43 from $33 at Citi
Citi analyst Jason Bazinet raised his price target for WWE to $43 citing increased TV rights forecasts. The stock is allying as investors await announcements on TV rights renewals, Bazinet tells investors in a research note. At $41 per share, the market is pricing an 80% step up in TV rights, which is possible, the analyst estimates. He notes that average sports step up is 50%. The analyst keeps a Neutral rating on WWE.
05/04/18
BNCH
05/04/18
DOWNGRADE
BNCH
Hold
WWE downgraded to Hold from Buy at Benchmark
Benchmark analyst Mike Hickey downgraded WWE to Hold from Buy citing valuation after the stock's 109% rise over the last year. Investor speculation is net positive on the company's upcoming TV rights fee negotiations, Hickey added.
05/17/18
GUGG
05/17/18
NO CHANGE
Target $48
GUGG
Buy
WWE likely to see 'favorable' TV deal renewal terms, says Guggenheim
Guggenheim analyst Curry Baker is keeping his Buy rating and $48 price target on WWE, saying he is "bullish" on the company's TV renewal prospects based on the terms about to be achieved by UFC. Baker says UFC is "on the verge" of renewing its TV right at over $350M in average annual value, which he calls a "baseline minimum" for WWE considering that its RAW and SmackDown programs provide more hours of content - 260 vs. UFC's 105 - and at much higher TV ratings than UFC.
BPMC Blueprint Medicines
$86.12

5.22 (6.45%)

04/16/18
JMPS
04/16/18
NO CHANGE
Target $109
JMPS
Outperform
Blueprint price target raised to $109 after BLU-667 data at JMP Securities
JMP Securities analyst Konstantinos Aprilakis raised his price target on Blueprint Medicines to $109 from $97 after the company presented data from the Phase I ARROW trial of BLU-667 in patients with solid tumors driven by alterations in RET at the American Association for Cancer Research annual meeting. Among all 53 enrolled patients, an "impressive" 41 patients remained on BLU-667 as of the data cutoff date, Aprilakis noted. He reiterates an Outperform rating on Blueprint shares.
PLCE Children's Place
$137.85

2.55 (1.88%)

05/14/18
OPCO
05/14/18
UPGRADE
OPCO
Outperform
Children's Place upgraded to Outperform from Perform at Oppenheimer
03/23/18
03/23/18
DOWNGRADE

Underperform
Children's Place downgraded to Underperform from Buy at BofA/Merrill
BofA/Merrill analyst Stephen Albert downgraded Children's Place two notches to Underperform from Buy and slashed its price target to $115 from $175 following the reduction in 2018 guidance. Management now expects 2018 core earnings of up 2-6% versus growth of 51% and 28% in FY16/17. Albert views management's 2020 earnings target of $12 as "ambitious," and even if it is achieved, would represent peak earnings, which deserves a lower multiple.
05/14/18
05/14/18
UPGRADE
Target $150

Outperform
Children's Place upgraded to Outperform at Oppenheimer
As previously reported, Oppenheimer analyst Anna Andreeva upgraded Children's Place to Outperform from Perform and raised her price target on the shares to $150 from $135, citing multiple initiatives still ahead while expectations re-set.
04/23/18
RILY
04/23/18
NO CHANGE
Target $167
RILY
Buy
Children's Place added to Alpha Generator List at B. Riley FBR
B. Riley FBR analyst Susan Anderson added Children's Place to her firm's Alpha Generator List. She has a Buy rating on the shares with a $167 price target.

TODAY'S FREE FLY STORIES

MSFT

Microsoft

$113.24

1.05 (0.94%)

20:52
09/18/18
09/18
20:52
09/18/18
20:52
Hot Stocks
Microsoft announces new AI and mixed reality business applications for Dynamics »

In its official blog,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 28

    Oct

  • 03

    Mar

BWA

BorgWarner

$42.99

-1.17 (-2.65%)

19:34
09/18/18
09/18
19:34
09/18/18
19:34
Hot Stocks
BorgWarner sees operating margins in low-13% by FY23 vs 12.4% in FY17 »

As part of its Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 25

    Oct

JLL

Jones Lang LaSalle

$144.15

0.795 (0.55%)

19:31
09/18/18
09/18
19:31
09/18/18
19:31
Hot Stocks
Jones Lang LaSalle CFO Christie Kelly resigns »

Jones Lang LaSalle…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

RACE

Ferrari

$138.31

5.465 (4.11%)

19:24
09/18/18
09/18
19:24
09/18/18
19:24
Earnings
Ferrari sees FY18 revenue over EUR3.4B »

As part of its Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

SMRT

Stein Mart

$1.97

-0.09 (-4.37%)

, INAP

Internap

$12.39

-0.33 (-2.59%)

19:02
09/18/18
09/18
19:02
09/18/18
19:02
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: Stein Mart (SMRT)…

SMRT

Stein Mart

$1.97

-0.09 (-4.37%)

INAP

Internap

$12.39

-0.33 (-2.59%)

TRVG

Trivago

$5.13

0.26 (5.34%)

PRQR

ProQR Therapeutics

$20.25

-1.4 (-6.47%)

MSFT

Microsoft

$113.24

1.05 (0.94%)

EVOP

EVO Payments

$26.27

-0.42 (-1.57%)

TSM

TSMC

$43.57

-0.2 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 28

    Oct

  • 12

    Nov

  • 15

    Nov

  • 03

    Mar

  • 21

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$290.96

1.55 (0.54%)

18:58
09/18/18
09/18
18:58
09/18/18
18:58
Periodicals
China to place new tariffs on $60B in U.S. exports, WSJ says »

China's government…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$290.96

1.55 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SQ

Square

$87.97

1.1 (1.27%)

18:55
09/18/18
09/18
18:55
09/18/18
18:55
Periodicals
Square seeks to bring 'omnichannel' experience to restaurants, CNBC says »

Square CFO Sarah Friar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

  • 20

    Sep

  • 26

    Sep

MSFT

Microsoft

$113.24

1.05 (0.94%)

18:48
09/18/18
09/18
18:48
09/18/18
18:48
Hot Stocks
Microsoft confirms raised quarterly dividend payment to 46c from 42c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 28

    Oct

  • 03

    Mar

KL

Kirkland Lake Gold

$17.57

-0.64 (-3.51%)

18:39
09/18/18
09/18
18:39
09/18/18
18:39
Hot Stocks
Kirkland Lake Gold acquires shares of Osisko Mining »

Kirkland Lake Gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

MSFT

Microsoft

$113.24

1.05 (0.94%)

18:39
09/18/18
09/18
18:39
09/18/18
18:39
Hot Stocks
Breaking Hot Stocks news story on Microsoft »

Microsoft raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 28

    Oct

  • 03

    Mar

OMAB

OMA Airports

$56.18

2.13 (3.94%)

18:23
09/18/18
09/18
18:23
09/18/18
18:23
Downgrade
OMA Airports rating change at Santander »

OMA Airports downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$113.41

-0.03 (-0.03%)

18:01
09/18/18
09/18
18:01
09/18/18
18:01
Hot Stocks
Celanese raises prices for acetate tow in Eastern Europ and Asia by $1/kg »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$132.97

0.56 (0.42%)

17:58
09/18/18
09/18
17:58
09/18/18
17:58
Periodicals
Wynn sued over allegations of rigging Boston casino bid, Bloomberg says »

Wynn Resorts and former…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$113.43

-0.18 (-0.16%)

17:48
09/18/18
09/18
17:48
09/18/18
17:48
Hot Stocks
SPDR Gold Trust holdings fall to 742.23MT from 742.53MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAZZ

Jazz Pharmaceuticals

$161.89

0.92 (0.57%)

17:35
09/18/18
09/18
17:35
09/18/18
17:35
Recommendations
Jazz Pharmaceuticals analyst commentary at BMO Capital »

Jazz Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 27

    Oct

  • 27

    Nov

  • 20

    Dec

RIG

Transocean

$11.93

0.335 (2.89%)

17:29
09/18/18
09/18
17:29
09/18/18
17:29
Initiation
Transocean initiated at Morgan Stanley »

Transocean initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NE

Noble Corp.

$6.15

0.19 (3.19%)

17:26
09/18/18
09/18
17:26
09/18/18
17:26
Initiation
Noble Corp. initiated at Morgan Stanley »

Noble Corp. initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

CCOEY

Capcom

17:24
09/18/18
09/18
17:24
09/18/18
17:24
Periodicals
Capcom shutting down Vancouver studio, Kotaku says »

Capcom Vancouver,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBY

Best Buy

$77.70

0.67 (0.87%)

17:24
09/18/18
09/18
17:24
09/18/18
17:24
Syndicate
Breaking Syndicate news story on Best Buy »

Best Buy files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DO

Diamond Offshore

$17.86

0.55 (3.18%)

17:22
09/18/18
09/18
17:22
09/18/18
17:22
Initiation
Diamond Offshore initiated at Morgan Stanley »

Diamond Offshore…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSM

TSMC

$43.57

-0.2 (-0.46%)

17:20
09/18/18
09/18
17:20
09/18/18
17:20
Upgrade
TSMC rating change at Morgan Stanley »

TSMC upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHD

Cactus

$35.93

1.24 (3.57%)

17:17
09/18/18
09/18
17:17
09/18/18
17:17
Initiation
Cactus initiated at Morgan Stanley »

Cactus initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZTCOY

ZTE Corp.

$0.00

(0.00%)

17:15
09/18/18
09/18
17:15
09/18/18
17:15
Periodicals
Senators seek punishment if ZTE strays from deal, Reuters says »

In a bill, introduced on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKCA

Akcea Therapeutics

$26.58

1.73 (6.96%)

17:15
09/18/18
09/18
17:15
09/18/18
17:15
Syndicate
Breaking Syndicate news story on Akcea Therapeutics »

Akcea Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Oct

OIS

Oil States

$30.85

0.55 (1.82%)

17:13
09/18/18
09/18
17:13
09/18/18
17:13
Initiation
Oil States initiated at Morgan Stanley »

Oil States initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.